End-of-day quote
Taipei Exchange
18:00:00 2024-05-12 EDT
5-day change
1st Jan Change
92.6
TWD
-0.75%
-0.86%
-12.23%
PharmaEngine : to attend 1H22 financial status investor conference hosted by Cathay Securities
July 26, 2022 at 05:19 am
Provided by: PharmaEngine, Inc.
SEQ_NO
4
Date of announcement
2022/07/26
Time of announcement
17:09:40
Subject
PharmaEngine Inc. to attend 1H22 financial
status investor conference hosted by Cathay Securities
Date of events
2022/07/27
To which item it meets
paragraph 12
Statement
1.Date of institutional investor conference:2022/07/27
2.Time of institutional investor conference:14:00
3.Location of institutional investor conference:Live streaming
4.Outline of institutional investor conference:
Announcement of 1H22 financial status and the FY22 outlook.
5.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 26 July 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 26 July 2022 09:18:05 UTC .
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-01
CI
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors
04-24
CI
PharmaEngine, Inc. Announces ONIVYDE Obtains TFDA Approval for New Regimen in First-Line Treatment of Metastatic PDAC
03-18
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-12
CI
PharmaEngine, Inc. Announces Consolidated Revenue Results for the Month and Year Ended December 2023
02-29
CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-06
CI
TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers
23-09-22
CI
PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of Pep07 for Hematological Cancers
23-08-15
CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-04
CI
PharmaEngine, Inc. Announces Dividend, Payable on September 1, 2023
23-07-27
CI
PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application
23-07-11
CI
PharmaEngine, Inc. Files Post-Approval Change Application for A New Indication of ONIVYDE to TFDA
23-06-21
CI
PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA
23-06-14
CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-04
CI
PharmaEngine, Inc. Announces Resignation of Peter Wu as Senior Director of Marketing & Sales
23-04-27
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-17
CI
Australia HREC Approves and Australia TGA Acknowledges PharmaEngine, Inc.'s Phase 1 Clinical Study of PEP07
23-03-03
CI
PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-04
CI
PharmaEngine, Inc. Announces Change of Board of Directors Chairperson
22-09-01
CI
PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022
22-08-30
CI
PharmaEngine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-03
CI
Pharmaengine, Inc. Announces Dividend for 2021,Payment Date of Cash Dividend Distribution Is September 2, 2022
22-07-26
CI
Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee
22-05-27
CI
PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-06
CI
PharmaEngine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
More about the company
Last Close Price
92.6
TWD
Average target price
106
TWD
Spread / Average Target
+14.47%
Consensus
1st Jan change
Capi.
-12.23% 413M +26.37% 44.96B -1.01% 42.65B +46.00% 41.85B -5.31% 29.04B +9.34% 26.08B -21.69% 19.03B +6.23% 12.75B +26.99% 12.06B -3.38% 11.75B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1